Christopher W Carreras
Overview
Explore the profile of Christopher W Carreras including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
227
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Henise J, Hangasky J, Charych D, Carreras C, Ashley G, Santi D
Sci Rep
. 2024 Jun;
14(1):14000.
PMID: 38890412
Intratumoral (IT) therapy is a powerful method of controlling tumor growth, but a major unsolved problem is the rapidity that injected drugs exit tumors, limiting on-target exposure and efficacy. We...
2.
Carreras C, Fontaine S, Reid R, Ashley G, Santi D
Bioconjug Chem
. 2024 Apr;
35(4):551-558.
PMID: 38591781
Poly(ADP-ribose) polymerase inhibitors (PARPi) have been approved for once or twice daily oral use in the treatment of cancers with BRCA defects. However, for some patients, oral administration of PARPi...
3.
Fontaine S, Carreras C, Reid R, Ashley G, Santi D
Cancer Res Commun
. 2023 Jun;
3(5):908-916.
PMID: 37377899
Significance: A circulating conjugate that slowly releases Exa is described. It is efficacious after a single dose and synergistic with ATR and PARP inhibitors.
4.
Jacobs J, Leadbetter M, Bell N, Koo-McCoy S, Carreras C, He L, et al.
ACS Med Chem Lett
. 2022 Jul;
13(7):1043-1051.
PMID: 35859876
We present herein the design, synthesis, and optimization of gut-restricted inhibitors of Na/H exchanger isoform 3 (NHE3). NHE3 is predominantly expressed in the kidney and gastrointestinal tract where it acts...
5.
Schneider E, Carreras C, Reid R, Ashley G, Santi D
Proc Natl Acad Sci U S A
. 2022 Jul;
119(30):e2201067119.
PMID: 35858423
The C-natriuretic peptide (CNP) analog vosoritide has recently been approved for treatment of achondroplasia in children. However, the regimen requires daily subcutaneous injections in pediatric patients over multiple years. The...
6.
Finn P, Rodriguez D, Kohler J, Jiang Z, Wan S, Blanco E, et al.
Am J Physiol Gastrointest Liver Physiol
. 2019 Jan;
316(3):G412-G424.
PMID: 30605011
Takeda G protein-coupled receptor 5 (TGR5) agonists induce systemic release of glucagon-like peptides (GLPs) from intestinal L cells, a potentially therapeutic action against metabolic diseases such as nonalcoholic steatohepatitis (NASH),...
7.
Chen T, Reich N, Bell N, Finn P, Rodriguez D, Kohler J, et al.
J Med Chem
. 2018 Aug;
61(17):7589-7613.
PMID: 30141927
Bile acid signaling and metabolism in the gastrointestinal tract have wide-ranging influences on systemic disease. G protein-coupled bile acid receptor 1 (GPBAR1, TGR5) is one of the major effectors in...
8.
Labonte E, Carreras C, Leadbetter M, Kozuka K, Kohler J, Koo-McCoy S, et al.
J Am Soc Nephrol
. 2014 Nov;
26(5):1138-49.
PMID: 25404658
In CKD, phosphate retention arising from diminished GFR is a key early step in a pathologic cascade leading to hyperthyroidism, metabolic bone disease, vascular calcification, and cardiovascular mortality. Tenapanor, a...
9.
Spencer A, Labonte E, Rosenbaum D, Plato C, Carreras C, Leadbetter M, et al.
Sci Transl Med
. 2014 Mar;
6(227):227ra36.
PMID: 24622516
The management of sodium intake is clinically important in many disease states including heart failure, kidney disease, and hypertension. Tenapanor is an inhibitor of the sodium-proton (Na(+)/H(+)) exchanger NHE3, which...
10.
Liu Y, Carreras C, Claypool M, Myles D, Shaw S
Bioorg Med Chem Lett
. 2011 May;
21(12):3712-4.
PMID: 21570844
The role of the erythromycin 4''-hydroxyl group has been explored on the motilin agonist potential in the 9-dihydroerythromycin series of motilides. The compounds show potencies 2- to 4-fold superior to...